Dr. Knight is investigating the use of biocompatible nanoparticles as in vivo diagnostic imaging agents. The nanoparticles are targeted to molecular markers of disease and are detectable by imaging methods such as magnetic resonance imaging. It is hoped that disease-specific nanoparticles can be used to carry therapeutic agents as well as being used to provide initial diagnosis and monitoring of the progress of therapy. This work is an outgrowth of Dr. Knight’s work on physiologic imaging using radiotracers.
For more information, please visit Dr. Knight’s website.
NTI: Signs of Success
NTI research programs have been extremely successful at publishing in peer-reviewed journals, resulting in more than 820 articles.
In addition, NTI researchers have been awarded more than 200 federal grants totaling more than $150 million.